Small molecule targeted inhibition of IL-6 or STAT3 promotes Treg development and leads to the establishment of homeostasis between Treg and Th17 cells in a model of multiple sclerosis (MS) (167, 168). The gene discussed is IL6; the disease is myeloid sarcoma.